---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344623"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-08-11T20:08:50+00:00"
generated_at: "2026-08-11T20:10:07.835664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Q2 net loss widens to $19.6M; Phase 3 PAH trial advances with $50M financing

## Summary
- Q2 2026 net loss $19.6M ($0.11/share) vs $9.9M loss in Q2 2025; R&D spend up to $13.4M from $5.3M.
- Cash, equivalents, and marketable securities $159.0M at June 30, 2026; plus $50M gross from 25M shares sold to RA Capital in July 2026.
- FDA granted Orphan Drug Designation for IKT-001 in July 2026; Phase 3 IMPROVE-PAH approvals in 26 countries, 43 sites initiated.
- Company expects existing and new capital to fund operations through Part B topline data readout, assuming warrant exercise.
- Pre-clinical/Phase 1 data at ATS showed improved GI profile vs imatinib and 18-fold lower c-Kit inhibition.

## SEC filing metadata
- accession: 0001193125-26-344623
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-08-11T20:08:50+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/0001193125-26-344623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344623
- JSON: https://secwatch.observer/filing/0001193125-26-344623.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344623.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.